IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B.
Chua C, Salimzadeh L, Ma AT, Adeyi OA, Seo H, Boukhaled GM, Mehrotra A, Patel A, Ferrando-Martinez S, Robbins SH, La D, Wong D, Janssen HLA, Brooks DG, Feld JJ, Gehring AJ.
Chua C, et al. Among authors: robbins sh.
Hepatol Commun. 2023 Dec 7;7(12):e0337. doi: 10.1097/HC9.0000000000000337. eCollection 2023 Dec 1.
Hepatol Commun. 2023.
PMID: 38055623
Free PMC article.